Company Profile
Vitranu’s patent pending TERC™ technology, the innovative Tunable Extended-Release Capsule for sustained delivery of therapeutics, aims to meet this need by reducing eye injections to 2 per year or fewer.
Vitranu’s patent pending TERC™ technology, the innovative Tunable Extended-Release Capsule for sustained delivery of therapeutics, aims to meet this need by reducing eye injections to 2 per year or fewer.